Company Overview

Cephalon was founded in 1987 with $3 million, 3 employees, and a single promising drug compound. Today the company has expanded beyond the U.S., with its European headquarters in England and offices in France and Germany. The firm markets three proprietary drugs in the U.S. (Provigil, Gabitril, and Actiq) plus another 25 drugs internationally. It has numerous drugs in various stages of testing and research. Expanding on an already existing product, Cephalon recently received FDA approval to market its drug Provigil for other symptoms of neurological sleep disorders.